The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Denosumab Does Not Increase Risk of Infection in RA Patients

Denosumab Does Not Increase Risk of Infection in RA Patients

February 13, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Postmenopausal women with rheumatoid arthritis (RA) and osteoporosis require treatment for both conditions. One option for physicians is to prescribe oral bisphosphonates, which chemically bind to calcium hydroxyapatite in bone and decrease bone resorption without blocking the formation of osteoclasts. Alternatively, physicians can now prescribe denosumab, which was approved by the U.S. Food and Drug Administration in 2010 as a treatment for post-menopausal osteoporosis.

You Might Also Like
  • FDA Approves Updated Labeling on Risk of Osteonecrosis of the Jaw for Denosumab
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
Also By This Author
  • State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

Denosumab is distinct from a bisphosphonate; it acts on osteoclasts and their precursors to prevent the interaction of RANKL with RANK, its receptor. Thus, denosumab blocks the formation, function and survival of osteoclasts. It is given subcutaneously twice a year, and its use has been associated with a reduction in the risk of vertebral, nonvertebral and hip fractures. The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial demonstrated that denosumab is more effective in reducing the risk of vertebral fracture than other oral osteoporosis agents.1 It is also effective at reducing bone resorption and can increase bone mineral density in the lumbar spine and hip.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

RANKL and RANK, the denosumab drug targets, belong to the tumor necrosis factor (TNF) superfamily and are also expressed on a variety of lymphoid cells, including activated T and B lymphocytes. Their presence on these cells has prompted concerns that the use of denosumab may increase the risk of cancer and infection. Although clinical trials have not revealed such increases, concerns remain that vulnerable individuals will experience an intolerable increase in infection. One such vulnerable subpopulation is women with RA who are prescribed TNF inhibitors or other biologics that are themselves associated with increased risk of infections.

At the 2016 ACR/ARHP Annual Meeting, Purva Chhibar, MD, rheumatology fellow, and Glenn Ehresmann, MD, rheumatologist, at the University of Southern California in Los Angeles presented the results of their retrospective chart review in a poster session. They sought to determine the rate of infections in patients prescribed a combination therapy of denosumab and either TNF inhibitors or other biologics. The investigators reviewed data from 40 patients in their rheumatology clinic who had been on denosumab and a TNF inhibitor/other biologic for five years.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The postmenopausal women (age 70 ± 9.8 years) had a diagnosis of RA and most (70%) were on TNF inhibitors, with only 30% on other biologics. “In our experience, the addition of denosumab to biologics, including TNF inhibitors, for patients with RA, for an average of five years of therapy, did not increase the risk of infection beyond what would have been expected for the patients’ disease, comorbidities and medications,” writes Dr. Chhibar in an email to The Rheumatologist.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: 2016 ACR/ARHP Annual Meeting, ACR/ARHP Annual Meeting, denosumab, Infection, Osteoporosis, Rheumatoid Arthritis (RA)

You Might Also Like:
  • FDA Approves Updated Labeling on Risk of Osteonecrosis of the Jaw for Denosumab
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis
  • Denosumab Does Not Stimulate Early Bone Formation

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)